STRENGTH
Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia (STRENGTH)
- Stage
- klaar
- Medicine
- epanova
- Population
- ASCVD
- Phase
- III
- First Patient In
- 15 February 2015
- Last Patient In
- 14 April 2017
- Last Patient Last Visit
- 31 August 2020
National Lead
dr. mr. A.J.M. Oude Ophuis
Cardioloog
Study Director
